Novo Nordisk (NVO) announced Saturday that its pending acquisition of three Catalent (NYSE:CTLT) production sites is expected to close within days as its parent entity satisfied all regulatory ...
Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its ...
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Moreover, free cash flow turned negative at minus DKK14.7 billion, largely due to heavy capital expenditures and the Catalent acquisition. Despite these challenges, Novo Nordisk remains well ...
Eli Lilly has called on financial regulators to look into the antitrust implications of Novo Holdings' purchase of Catalent and the sale of three manufacturing facilities to Novo Nordisk.
Novo Nordisk also reported the acquisition of three manufacturing sites from Novo Holdings A/S following the finalization of Novo Holdings' acquisition of Catalent, Inc. - a global contract ...
Catalent is a global contract development and manufacturing organisation headquartered in New Jersey (US). The parties are now free to close the transaction, as well as Novo Nordisk’s subsequent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback